* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Implications For Transition-State Analogs And Catalytic
Biochemistry wikipedia , lookup
Ligand binding assay wikipedia , lookup
Photosynthetic reaction centre wikipedia , lookup
Polyclonal B cell response wikipedia , lookup
Evolution of metal ions in biological systems wikipedia , lookup
Glass transition wikipedia , lookup
Immunoprecipitation wikipedia , lookup
Catalytic triad wikipedia , lookup
Metalloprotein wikipedia , lookup
Deoxyribozyme wikipedia , lookup
Catalytic Antibody – AZ-28 Oxy Cope Rearrangement Biocatalyst CHEM*4450 – Biochemistry and Structure of Macromolecules Seminar Series Presented By: Woo-Jin Yoo Seminar Outline 1. Introduction 2. Implications For Transition-State Analogs And Catalytic Antibodies 3. AZ-28: Oxy-Cope Rearrangement Catalytic Antibody 4. Structure And Function Relationship Of AZ-28 With Transition State Analog 5. Structure And Function Relationship Of AZ-28 And Germline Antibody 6. Concluding Remarks 7. References Introduction Rationale for the development of biocatalyst Advantages: • high regio- and stereoselectivity • environmentally friendly • non-toxic Biocatalysts: enzymes, bioengineered microorganisms, ribozymes, catalytic antibodies Advantage of catalytic antibodies: Potential to design a biocatalyst for a specific reaction Implications For Transition-State Analogs And Catalytic Antibodies How do enzymes accelerate chemical reactions? For one substrate to product situation: Corresponding Energy Diagram: Enzymes accelerate chemical reactions by stabilizing the transition state. What are the available physical/chemical forces available for binding and catalysis? •Van der Waal •Hydrogen bonding •Hydrophobic effect •Ionic Interactions Designing a protein to catalyze a chemical reaction: Idea: Proteins which binds transition state strongly should be able to catalyze a chemical reaction Application: Immunize an animal using a transition state analog as a hapten to form antibodies that bind to the transition state analog Example: Oxy-Cope rearrangement catalytic antibody AZ-28 1. Determination and synthesis of the hapten (transition state analog) 2. Attachment of hapten to a macromolecule BSA = Bovine Serum Albumin KLH = Keyhole Limpet Hemocyanin 3. Preparation of monoclonal antibodies AZ-28: Oxy-Cope Rearrangement Catalytic Antibody Background Information • rearrangement is based on a diradical, cyclohexane TS intermediate • driven by the formation of a keto-enol compound Why is this reaction slow/not possible at room temperature? • transition state is a six-membered ring in the chair conformation • in solution, there are possible rotation of sigma bonds Hapten design: Rationale • transition state is a cyclohexane intermediate • • strong preference for aromatic rings for catalytic antibodies CONH(CH2)3COOH – is the tether to BSA/KLH Structure And Function Relationship Of AZ28 With Transition State Analog AZ-28: Unliganded Mature OxyCope Catalytic Antibody Binding interactions between AZ-28 and Transition State Analog 5-phenyl group • at the bottom of cavity • surrounded by large number of aromatic and hydrophobic residues • -stacking with H103His 2-phenyl group • at the opening of the binding pocket • orientation is fixed by -stacking with H96His and van der waal interaction with side chain of L91Tyr Cyclohexane ring • position fixed by H-bonding with OH group and the imidazole ring of H96His • van der waal contact with L33Asn H101Asp Mechanistic proposal for the Oxy-Cope rearrangement with AZ-28 1. Entopic Effect Extended conformation is fixed into the energetically unfavorable conformation by the binding site of the antibody G = H - TS Fixing conformation = S , G 2. Electronic Effect Side chain of H96His and H-bonding of bridging water to H50Glu increases the electron density of oxygen Increased electron density on the oxygen will increase the rate of Oxy-Cope rearrangement Structure And Function Relationship Of AZ-28 And Germline Antibody Fab of Mature Antibody Fab of Germline Antibody What the heck is going on? AZ-28 binds the TS analog more tightly than the germline antibody, but the germline antibody is a better catalyst Comparison of AZ-28 with germline antibody AZ-28 bound with TSA germline bound with TSA Reason for increased catalysis of germline antibody Recall: The transition state of the Oxy-Cope rearrangement is a diradical The radical can be stabilized by the aromatic group Molecular orbital reasons for increased catalytic activity Note: stabilization of the transition state decreases the energy requirements for catalysis When radical is in the same plane as aromatic ring When radical is perpendicular to the aromatic ring • The germline antibody fixes the TSA so that the aromatic rings are 63.2o (5-phenyl) and 57.9o (2-phenyl) to the cyclohexane framework • AZ-28 fixes the TSA so that the aromatic rings are 81o (5-phenyl) and 85o (2-phenyl) to the cyclohexane framework Electron density diagram of the active site for AZ-28 Structural reasons for difference in aromatic ring angle between AZ-28 and germline antibody Primary sequence difference Structural basis for catalytic properties of germline and affinity matured antibody Only L34 amino acid residue is at the active site AZ-28 – L34Asn Germline – L34Ser Liganded AZ-28 – 2.6 Å Unliganded AZ-28 – 3.2 Å Liganded Germline – 3.0 Å Unliganded Germline – 3.7 Å Result: Increased flexibility of active site for germline antibody lowers the rotational barrier for the C2-phenyl Concluding Remarks Comments: AZ-28 binds more tightly to the TSA than germline antibody. However, germline antibody is a better catalyst Reason: Flaw in the design of TSA. True TS possess sp2 carbons attached to the aromatic groups. TSA have sp3 carbons and in solution, the aromatic groups prefer to be perpendicular to the cyclohexane framework References 1. 2. 3. 4. 5. Ulrich, H.D., Mundorff, E.C., Santarsiero, B.D., Driggers, E.M., Stevens, R.C., and Schultz, P.G. (1997) Nature 389, 271-275. Driggers, E.M., Cho, H.S., Liu, C.W., Katzka, C.P., Braisted, A.C., Ulrich, H.D., Wemmer, D.E. and Schultz, P.G. (1998) J. Am. Chem. Soc., 120, 1945-1958. Mundorff, E.C., Hanson, M.A., Varvak, A., Ulrich, H.D., Schultz, P.G., and Stevens, R.C. (2000) Biochemistry 39, 627-632. Braisted, A.C. and Schultz, P.G. (1994) J. Am. Chem. Soc., 116, 2211-2212. Mader, M.M., and Bartlett, P.A. (1997) Chem. Rev., 97, 1281-1301.